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Abstract
Background
Podoconiosis is a disease of the lymphatic vessels of the lower extremities that is caused by
chronic exposure to irritant soils. It results in leg swelling, commonly complicated by acute
dermatolymphangioadenitis (ADLA), characterised by severe pain, fever and disability.
Methods
We conducted cost-effectiveness and social outcome analyses of a pragmatic, randomised
controlled trial of a hygiene and foot-care intervention for people with podoconiosis in the
East Gojjam zone of northern Ethiopia. Participants were allocated to the immediate inter-
vention group or the delayed intervention group (control). The 12-month intervention
included training in foot hygiene, skin care, bandaging, exercises, and use of socks and
shoes, and was supported by lay community assistants. The cost-effectiveness analysis
was conducted using the cost of productivity loss due to acute dermatolymphangioadenitis.
Household costs were not included. Health outcomes in the cost-effectiveness analysis
were: the incidence of ADLA episodes, health-related quality of life captured using the Der-
matology Life Quality Index (DLQI), and disability scores measured using the WHO Disabil-
ity Assessment Schedule 2.0 (WHODAS 2.0).
Results
The cost of the foot hygiene and lymphoedema management supplies was 529 ETB (69 I$,
international dollars) per person per year. The cost of delivery of the intervention as part of
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the trial, including transportation, storage, training of lay community assistants and adminis-
tering the intervention was 1,890 ETB (246 I$) per person. The intervention was effective in
reducing the incidence of acute dermatolymphangioadenitis episodes and improving DLQI
scores, while there were no significant improvements in the disability scores measured
using WHODAS 2.0. In 75% of estimations, the intervention was less costly than the control.
This was due to improved work productivity. Subgroup analyses based on income group
showed that the intervention was cost-effective (both less costly and more effective) in
reducing the number of acute dermatolymphangioadenitis episodes and improving health-
related quality of life in families with monthly income <1,000 ETB (130 I$). For the subgroup
with family income�1,000 ETB, the intervention was more effective but more costly than
the control.
Conclusions
Whilst there is evident benefit of the intervention for all, the economic impact would be great-
est for the poorest.
Author summary
Podoconiosis is a disease of the lymphatic vessels of the lower extremities that is caused by
chronic exposure to irritant soils. The condition has been reported from 32 countries
around the world, and is common in low-resource settings in which people do not wear
shoes as protection against the soil. It results in leg swelling, commonly complicated by
acute dermatolymphangioadenitis (ADLA, or ‘acute attacks’), characterised by severe
pain, fever and disability. A low-cost, lay-led treatment package to prevent ADLA and
reverse early stages of disease was tested in northern Ethiopia in 2014–2015. The package
involves daily foot hygiene, skin care elastic bandaging where necessary, exercises, eleva-
tion and regular use of socks and shoes. In this study we report the impact of this package
on quality of life and decreasing work productivity losses.
Introduction
Podoconiosis is a form of leg swelling due to lymphoedema arising from exposure to red clay
soils derived from alkalic volcanic rock [1]. It is most prevalent in extremely poor subsistence
farming communities who spend the majority of their time working barefoot in irritant soils.
Podoconiosis results in debilitating mobility issues, affecting persons’ earning ability and qual-
ity of life, in particular, due to acute dermatolymphangioadenitis episodes (ADLA) character-
ised by severe pain, fever and disability.
A recent systematic review indicates that podoconiosis has been reported at some point in
time from 32 countries worldwide, 18 in the African Region, 3 in Asia and 11 in Latin America
[2]. The highest reported prevalence values were in Africa (8.08% in Cameroon, 7.45% in Ethi-
opia, 4.52% in Uganda, 3.87% in Kenya and 2.51% in Tanzania).
Podoconiosis leads to significant stigma and reduced quality of life [3–5]. It has significant
impact on productivity, with affected people losing 45% of total working days per year [6].
However, misdiagnosis (chiefly confusion with filarial lymphoedema) and fatalism have ham-
pered treatment [7]. Only in the past two decades has foot hygiene treatment been offered
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specifically to people with podoconiosis [8,9], and this has been initiated by non-government
organisations without state adoption or systematic evaluation. Based on the urgent need for
evidence on which to base national policy, a fully randomised controlled trial (RCT) of the
intervention was conducted in northern Ethiopia [10].
The Gojjam Lymphoedema Best Practice Trial (GoLBeT) was a pragmatic RCT designed to
evaluate the effectiveness of podoconiosis lymphoedema management in the community
(ISRCTN67805210). The RCT set out to test the hypothesis that community-based treatment
of podoconiosis lymphoedema reduces the frequency of acute dermatolymphangioadenitis
episodes and secondarily that it improves other clinical, social and economic outcomes. Podo-
coniosis patients aged 18 years and older were individually randomised to a package compris-
ing instruction in foot hygiene, skin care, bandaging, exercises, use of socks and shoes, with
support by lay Community Podoconiosis Agents (CPAs) at monthly intervention meetings; or
to no intervention. Full details of the RCT protocol and the Rapid Ethical Assessment that pre-
ceded recruitment are described in previous articles [10, 11]. The primary outcome results
have been published [12], as has detailed description of the screening and enrolment process
[13].
Although several economic analyses of lymphatic filariasis (LF) treatment exist and demon-
strate high cost-effectiveness [14], there are no previous estimates of the cost-effectiveness of
podoconiosis treatment. Here we present the results of a cost-effectiveness analysis of the GoL-
BeT trial, with scenario analysis to reflect the approach to provision of care promoted by the
Ethiopian Federal Ministry of Health [15].
Methods
Ethics statement
The study was approved by the Institutional Review Board of the College of Health Sciences,
Addis Ababa University (071/13/SPH), the National Ethical Review Committee of the Ethio-
pian Science and Technology Agency (3-1/794/06), the Food, Medicine and Health Care
Administration Authority of Ethiopia (02/6-1/05/39), and the Research Ethics and Gover-
nance Committee of Brighton and Sussex Medical School (13/107/DAV).
Data sources and study characteristics
Study design, setting and participants’ characteristics are described in detail elsewhere [10].
Briefly, participants were adults aged 18 years and older, with a diagnosis of at least stage 2
podoconiosis (persistent lymphoedema). Participants were individually randomised (1:1 ratio)
to the intervention or control groups. Participants randomised to the intervention group were
instructed in foot hygiene, skin care, bandaging, exercises, and use of socks and shoes, and
supported by lay community assistants at monthly meetings. Control patients were followed
up quarterly for data collection, but received no intervention for 12 months (delayed interven-
tion). The primary outcome was incidence of ADLA, measured using a validated patient-held
pictorial diary. Secondary outcomes included: quality of life measure using the Amharic ver-
sion of the Dermatology Life Quality Index II (DLQI) [16, 17]; disability scores measured
using the 12-item version of the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)
[18]; days totally unable to work and days with reduced productivity; stigma; and observed
clinical changes. The number of ADLA episodes and DLQI questionnaires were collected at
baseline, 3, 6, 9 and 12 months; family income data were collected at baseline, 6 and 12
months. WHODAS 2.0 questionnaires, days totally unable to work and days with reduced pro-
ductivity were collected at baseline and 12 months.
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Health economics analysis
The economic evaluation was conducted from a mixed perspective including a programme
implementation perspective and a patient perspective. Study participants were predominantly
unpaid subsistence farmers who produce food for their own consumption. Therefore, we ana-
lysed work productivity from a patient perspective (direct costs). Economic evaluation methods
followed the WHO guide to cost-effectiveness analysis [19], which includes recommendations
on estimating costs, health outcomes and assessing uncertainty in cost-effectiveness analysis.
Costing GoLBet intervention
The economic cost of the intervention was estimated using financial records and interviews
with project managers. Economic analysis was not anticipated in this study. Therefore, data on
resource use and associated costs were collected retrospectively. We used a micro-costing
approach involving bottom-up construction of costs associated with setting up and delivering
the intervention. The costing categories included: treatment supplies, storage and transporta-
tion; community assistants’ salaries; training community assistants; community podoconiosis
activities; education and awareness raising and administration costs. We excluded research
costs associated with trial set-up and data collection (e.g. research staff, computers, statistical
software, medical and life insurance, ethics approval and audit). The estimated cost of the
intervention per person was based on the number of participants enrolled in the trial (inten-
tion to treat). The average cost per participant was estimated with and without training to
reflect the fact that, once trained, the community assistants might continue to fulfil their duties
beyond the duration of the trial. The summary of intervention costs is shown in Table 1.
Health-related productivity loss
The loss of productivity due to podoconiosis illness was estimated by summing the number of
days unable to work and days with reduced activity. It was assumed that days with reduced
activity account for a 50% reduction in work productivity. This assumption was based on a
study which estimated that the cost of work presenteeism (all causes of illness) amounts to
approximately half of the cost of sickness absence [20].
The average number of days with lost productivity over 12 months was estimated using the
area-under-the curve method (trapezoidal) [21]. Productivity loss was costed using the average
daily wages (poor persons’ general consumer price index-deflated real wages) for unskilled rural
labour in Ethiopia [22]. This study was based on data on prevailing wages collected by Central
Statistical Agency of Ethiopia (2015). We used average wages for Amhara region in 2015 (37.1
ETB) [22, page 27]. All costs were converted to I$ and adjusted to the year 2016 using the Pur-
chasing Power Parity converter [23] to alleviate currency exchange rate fluctuations.
Effectiveness outcomes
The health economics analysis was conducted using three effectiveness outcomes: the number
of ADLA episodes, DLQI and WHODAS 2.0.
DLQI [16] is a dermatology-specific Quality of Life instrument, which was translated into
Amharic and validated among patients with podoconiosis in southern Ethiopia [17]. It consists
of 10 questions concerning patients’ perception of the impact of skin diseases on different
aspects of their life, including symptoms and feelings, daily activities, leisure, work or school
and personal relationships. Each question is scored on a 4-point Likert scale (0–3). The scores
of individual items are added together to yield a total score ranging from 0 to 30. Higher scores
mean lower quality of life [16].
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WHODAS 2.0 is the World Health Organization Disability Assessment Schedule, a generic
instrument for assessing health and disability [18]. It includes 12 items covering cognition,
mobility, self-care, interaction with people, life and community activities. The Amharic ver-
sion of WHODAS 2.0 was validated in people with severe mental disorders in rural Ethiopia
[24]. The items are rated using a 5-point Likert scale (1–5). Higher scores mean greater disabil-
ity. DLQI and WHODAS 2.0 total scores were calculated by adding the scores for each item.
To enable the cost-effectiveness analysis, the number of ADLA episodes, DLQI and WHODAS
2.0 for each participant were calculated over 12 months using the area-under-the curve
method (trapezoidal) [21].
Missing data
Multiple imputations [25, 26] were carried out using the predictive mean matching method
[27] in Stata 12.1. Missing data were assumed to be missing at random. For each missing
Table 1. Summary of set-up and operational costs of community-based treatment of podoconiosis lymphoedema.
Hygiene and treatment supplies Units Duration Resource use Unit cost, ETB Total cost,
ETB
Ointment 1 tube 12 months 100% 10 83,520
Soap 1 piece 12 months 100% 8 66,816
Shoes 1 pair once 99% 270 186,300
Socks 2 pairs once 100% 19 13,224
Basin 1 item once 100% 25 17,400
Bandages 1 pack once 5% 20 696
Sub-total (hygiene and treatment supplies) 367,956
Per patient (n = 696) 529
Intervention delivery Units Duration Resource use Unit cost, ETB Total cost,
ETB
Salaries
Community Assistants 15 12 months 950 171,000
Administrator 1 12 months 14,000 168,000
Storage of supplies 36 months lump sum sum 25,173
Transportation
Car rental 36 months lump sum 703,687
Fuel 36 months lump sum 141,587
Training community assistants 18 assistants 4 days initial training
+ 3 days refresher
2 trainers lump sum 27,600
Monthly meetings with patients
(18 kebele)
2–18 people 3 hours 2–3 assistants lump sum 55,000
Community education & awareness activities
Officials Sensitization Workshop 46 officials 3 hours 3 trainers
Community Sensitization
Workshops(4 kebele)
12–30 people 2 hours 2 trainers
Total (education & awareness) lump sum 23,595
Sub-total (delivery) 1,315,638
Per patient (n = 696) 1,890
Total cost of intervention 1,683,594
Cost per patient including training 2,419
Cost per patient excluding training 2,379
Numbers are rounded to nearest ETB (Ethiopian Birr)
https://doi.org/10.1371/journal.pntd.0007780.t001
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category, five datasets were imputed. For DLQI and WHODAS 2.0 the answers to missing
questions were imputed based on the following covariates: age, gender, randomisation group
and kebele (smallest administrative unit in Ethiopia). Missing data for days totally unable to
work and days with reduced activity were imputed based on the number of ADLA episodes,
age, gender, randomisation group and kebele. Missing data were not imputed for family
income or the number of ADLA episodes.
Cost-effectiveness analysis
The cost-effectiveness analysis was conducted on an intention-to-treat basis. We assessed the
incremental changes in costs associated with productivity loss due to illness and the incremen-
tal changes in the effectiveness outcomes: the number of ADLA episodes, DLQI and WHO-
DAS 2.0. Both costs and effectiveness outcomes were adjusted for covariates age, gender, and
kebele using three linear models: generalised linear model (GLM), seemingly unrelated regres-
sion (SUR) and multilevel mixed-effect model (MLM). The GLM model assumed gamma dis-
tribution and identity link. The SUR model included regression equations for both cost and
effectiveness outcomes, each regressed on the age, gender, and kebele. The MLM model
included age and gender as a fixed effect and kebele as a random effect. The incremental cost-
effectiveness ratio was calculated as a difference in cost between the immediate and delayed
groups divided by the difference in effectiveness outcome between the immediate and delayed
groups. A non-parametric bootstrap method was used to assess the uncertainty in cost-effec-
tiveness ratios. Results of cost-effectiveness analyses are presented as cost-effectiveness planes
(incremental cost plotted against the incremental outcome). Subgroup analyses were con-
ducted for individuals with two different levels of family income: lower (<1,000 ETB month)
and higher (�1,000 ETB/month), this cut-off being based on a baseline economic survey con-
ducted in a neighbouring district prior to the trial [28]. It should be mentioned that although
we divided participants into “lower” and “higher” income groups, they are all members of a
very poor population who often cannot afford shoes, socks, or even water to wash their feet.
Scenario analysis considered the cost of the intervention without training community assis-
tants, assuming that once trained they will continue fulfilling their duties.
Results
Intervention costs
Costs associated with set-up and delivery of community-based treatment for podoconiosis
lymphoedema are summarised in Table 1. These were divided into the costs of treatment sup-
plies and the costs of delivering the intervention. The treatment supplies included: Whitfield
ointment (one tube per month); soap (one piece per month); custom-made shoes (one pair);
socks (two pairs); bandages (one pair) and basin (one). Whitfield ointment and soap were pro-
vided over 12 months. Bandages were required for 5% of patients only. The average cost of
treatment supplies per participant was 529 ETB (69 I$). Costs associated with delivering the
intervention as part of the trial included: salaries (remuneration for community assistants and
administrator costs); storage of treatment supplies; transportation of treatment supplies, com-
munity engagement activities (two sensitization workshops), community podoconiosis activi-
ties (monthly meetings with patients), and training community assistants (two training
meetings). The total cost of the intervention per patient was 2,419 ETB (314 I$) with training
community assistants, and 2.379 ETB (309 I$) without training. It should be mentioned that it
was not possible to completely separate research costs from the intervention delivery costs,
therefore the latter may be inflated.
Cost-effectiveness of podoconiosis lymphoedema treatment in Ethiopia
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Dataset characteristics
Information about the completeness of the health economics dataset is summarised in S1
Appendix. Although the proportion of missing items for each variable was not large (0.3%-
21.5%), the complete dataset for health economics analysis was obtained for only 323 (from
650 total) participants (immediate group n = 120, delayed group n = 203). The complete data-
set comprised 50% of the total sample (immediate group n = 331, delayed group n = 329). To
minimise bias introduced by missing data, multiple imputation was carried out as described in
the Methods. The comparison of imputed and non-imputed datasets is shown in S2 Appendix.
Health and social outcomes
Costs and outcomes used in the cost effectiveness analyses are summarised in Table 2. The fre-
quency of ADLA episodes was lower in the immediate treatment group compared to the con-
trol group at 3, 6, 9 and 12 months, with a statistically significant difference at 3 and 12
months. The average number of ADLA episodes per year was 14.0 (SD 6.4) for the immediate
treatment group and 12.5 (SD 4.6) for the control group.
DLQI scores were lower in the immediate treatment group at all time-points following the
introduction of the intervention; all differences in the mean DLQI scores were statistically sig-
nificant. The mean DLQI scores calculated using the area-under-the-curve method were 9.13
(SD 4.15) for the immediate treatment group and 11.16 (SD 3.71) for the control group. The
differences between intervention and control groups remained apparent when sub-analyses by
gender, disease stage and kebele location, but were more pronounced among men than
women, individuals with early stages of lymphoedema (disease stage�2) and those who had
never attended school than those who had (Table 3).
There were no statistically significant differences in WHODAS 2.0 scores between the
immediate treatment group and the control group both at baseline and at 12 months. Sub-
group analyses by gender, disease stage, kebele location and education also showed no statisti-
cally significant differences at 12 months (Table 4).
Patients from the immediate treatment group had on average fewer days off work due to ill-
ness at 12 months compared to patients from the control group (Table 2). The estimated aver-
age number of days that patients were totally unable to work was 60 per year for the
immediate treatment group and 64 per year for the control group. The estimated average num-
ber of days with reduced activity was 49 per year for the immediate intervention group and 51
per year for the control group. The average monthly cost of work productivity loss at 12
months was lower in the intervention group, 252 ETB (33 I$) compared to the control group,
286 ETB (37 I$). The estimated average annual cost of productivity loss was 3,452 ETB (449 I
$) for the immediate treatment group and 3,644 ETB (474 I$) for the control group.
Cost-effectiveness analysis
Results of the base-case cost-effectiveness analysis were derived for the imputed dataset using
the generalised linear model. The total cost included in the cost-effectiveness analysis was cal-
culated as the cost of work productivity loss due to illness for the control group, and the cost of
intervention plus the cost of productivity loss for the immediate treatment group. The inter-
vention cost included the cost of training community podoconiosis assistants. Cost-effective-
ness analyses were carried out using the three effectiveness outcomes: the number of ADLA
episodes, DLQI and WHODAS 2.0 scores. The results of the base-case cost-effectiveness analy-
sis are summarised in Table 5.
Analysis based on the frequency of ADLA episodes showed that treatment was on average
less costly (negative difference in cost) and more effective (negative difference in the number
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of ADLA episodes) compared to control. The mean difference in cost was small, 22 ETB (3 I$)
and the confidence intervals were wide, indicating the possibility of the intervention being
overall more costly than control. Uncertainty around the incremental cost-effectiveness ratio
was assessed using the non-parametric bootstrap method. A cost-effectiveness plane depicting
5,000 bootstrap estimates is shown on Fig 1A. The graph demonstrates that in 75% of estima-
tions the immediate treatment was less costly and more effective in reducing the frequency of
ADLA episodes compared to control, and in 25% the immediate treatment was more costly
and more effective compared to control.
Cost-effectiveness analysis conducted using DLQI showed similar results with immediate
treatment being on average less costly and more effective than the control (Table 5). There was
a statistically significant difference in the DLQI scores between the two groups. Probabilistic
analysis showed that in 75% of simulations the immediate treatment was less costly and more
effective compared to control Fig 1B. In the remaining 25% of simulations the immediate
treatment was more costly and more effective compared to control.
Cost effectiveness analyses conducted using WHODAS 2.0 demonstrated that the interven-
tion was less effective in reducing disability in the immediate treatment group compared to the
control group, but the difference was very small (2.6% change in average scores) (Table 5). The
Table 2. Outcomes and costs used in cost-effectiveness analysis.
Outcome Control Immediate treatment P-Value
(Mann-Whitney test)N mean (SD) N mean (SD)
ADLA episodes/quarter
Baseline 317 2.79 (1.83) 303 3.01 (3.01) 0.95
3 months 309 3.47 (2.58) 267 3.02 (2.12) 0.00
6 months 295 3.20 (2.65) 240 3.04 (2.09) 0.91
9 months 294 3.27 (2.73) 223 2.99 (2.34) 0.12
12 months 285 3.21 (2.10) 225 2.61 (1.54) 0.00
DLQI�
Baseline 329 10.22 (5.59) 321 10.92 (6.24) 0.19
3 months 329 10.52 (7.13) 321 9.03 (6.72) 0.00
6 months 329 11.26 (6.55) 321 8.92 (7.00) 0.00
9 months 329 12.04 (5.87) 321 8.72 (6.71) 0.00
12 months 329 11.38 (6.29) 321 8.80 (6.87) 0.00
WHODAS 2.0�
Baseline 329 23.36(10.32) 321 24.69 (10.21) 0.13
12 months 329 22.04 (9.53) 321 21.76 (10.73) 0.96
Days totally unable to work/month
Baseline 329 5.58 (4.30) 321 5.65 (4.11) 0.75
12 months 329 5.08 (3.90) 321 4.38 (3.93) 0.00
Days with reduced activity/month
Baseline 329 4.59 (4.43) 321 4.55 (4.50) 0.45
12 months 329 3.86 (3.30) 321 3.59 (3.47) 0.06
Cost of productivity loss/year, ETB
Baseline 329 321 (238) 321 323 (227) 0.99
12 months 329 286 (205) 321 252 (208) 0.00
�Lower DLQI and WHODAS 2.0 scores indicate better outcome. DLQI, Dermatology Life Quality Index; WHODAS 2.0, WHO Disability Assessment Schedule 2.0;
ADLA, acute dermatolymphangioadenitis; ETB, Ethiopian Birr
https://doi.org/10.1371/journal.pntd.0007780.t002
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Table 3. Subgroup analyses using DLQI.
Variable Control Immediate treatment P-Value
(Mann-Whitney test)mean SD mean SD
Male
Baseline 10.21 5.65 11.17 6.52 0.20
3 months 10.82 7.30 9.07 6.85 0.01
6 months 11.46 6.47 8.22 6.88 0.00
9 months 12.29 6.17 8.60 6.89 0.00
12 months 10.98 6.62 8.45 6.90 0.00
Female
Baseline 10.24 5.50 10.60 5.90 0.57
3 months 10.18 6.90 10.00 6.57 0.15
6 months 11.04 6.62 10.00 7.03 0.08
9 months 11.75 5.47 9.00 6.49 0.00
12 months 11.84 5.85 10.00 6.79 0.00
Disease stage�2
Baseline 10.20 5.48 10.88 6.20 0.23
3 months 10.36 7.17 8.97 6.78 0.01
6 months 11.22 6.60 8.92 7.11 0.00
9 months 12.07 5.87 8.76 6.67 0.00
12 months 11.49 6.30 9.01 6.85 0.00
Disease stage >2
Baseline 10.48 6.73 12.50 6.74 0.36
3 months 12.56 6.14 10.50 5.42 0.17
6 months 11.80 5.72 9.00 4.67 0.10
9 months 11.64 5.71 8.50 7.02 0.05
12 months 10.04 5.94 2.50 6.03 0.01
Not attended school
Baseline 10.42 5.52 11.08 6.27 0.26
3 months 10.71 7.26 8.54 6.51 0.00
6 months 11.28 6.48 8.61 7.00 0.00
9 months 12.15 5.79 8.56 6.45 0.00
12 months 11.33 6.35 8.84 6.83 0.00
Attended school
Baseline 9.36 5.76 10.20 6.02 0.14
3 months 9.75 6.45 11.00 7.16 0.96
6 months 11.19 6.80 11.00 6.83 0.83
9 months 11.57 6.12 10.00 7.56 0.05
12 months 11.62 5.98 9.00 6.97 0.19
Close kebele
Baseline 10.05 5.12 11.82 5.70 0.04
3 months 10.82 7.14 8.45 6.74 0.02
6 months 12.13 6.29 8.36 6.60 0.00
9 months 13.17 4.86 7.60 5.99 0.00
12 months 12.50 5.79 8.34 6.49 0.00
Remote kebele
Baseline 10.32 5.82 10.00 6.43 0.87
3 months 10.36 7.11 10.00 6.68 0.08
6 months 10.78 6.63 9.00 7.16 0.02
(Continued)
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cost-effectiveness plane shows that in 75% of simulations the immediate treatment was less
effective and less costly, and in 25% of simulations the immediate treatment was less effective
and more costly compared to control (Fig 1C).
Sensitivity analyses were conducted using two different models (SUR and MLM) as well as
non-adjusted data (S3 Appendix). The cost-effectiveness estimates derived using different
models were close, indicating the robustness of the results.
Scenario analyses were conducted to account for training community podoconiosis assis-
tants as a part of the intervention cost (S4 Appendix). Removing training costs did not have a
pronounced effect on the results of the cost-effectiveness analysis.
Table 3. (Continued)
Variable Control Immediate treatment P-Value
(Mann-Whitney test)mean SD mean SD
9 months 11.41 6.26 10.00 6.95 0.00
12 months 10.76 6.45 9.20 7.02 0.00
Lower DLQI scores indicate better outcome. DLQI, Dermatology Life Quality Index
https://doi.org/10.1371/journal.pntd.0007780.t003
Table 4. Subgroup analyses using WHODAS 2.0.
Variable Control Immediate treatment P-Value
(Mann-Whitney test)N mean (SD) N mean (SD)
Male
Baseline 22.74 11.03 24.74 10.47 0.15
12 months 22.14 10.15 21.24 10.46 0.82
Female
Baseline 24.08 9.36 26.00 9.91 0.48
12 months 21.94 8.74 24.00 10.94 0.39
Disease stage�2
Baseline 23.16 10.31 24.54 10.18 0.11
12 months 22.07 9.60 21.98 10.71 0.88
Disease stage >2
Baseline 25.80 9.94 26.00 10.26 0.84
12 months 21.68 8.49 24.00 10.12 0.84
Not attended school
Baseline 23.71 10.56 25.50 9.82 0.09
12 months 22.20 9.52 21.63 10.82 0.79
Attended school
Baseline 21.92 8.99 22.50 11.00 0.87
12 months 21.37 9.45 25.00 10.24 0.66
Close kebele
Baseline 23.50 9.79 24.64 9.94 0.37
12 months 23.87 7.65 22.59 8.66 0.79
Remote kebele
Baseline 23.29 10.57 26.00 10.32 0.24
12 months 21.03 10.27 24.00 11.57 0.61
Lower WHODAS 2.0 scores indicate better outcome.; WHODAS 2.0, WHO Disability Assessment Schedule 2.0
https://doi.org/10.1371/journal.pntd.0007780.t004
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Subgroup analyses were carried out for patients with a range of family incomes. We sepa-
rated two subgroups of patients based on their baseline family income (<1,000 ETB/month
and�1,000 ETB/month). Results of the subgroup analyses adjusted for covariates using GLM
are summarised in Table 6.
For patients with lower family income the immediate treatment was less costly and more
effective than control in reducing the number of ADLA episodes. For patients with higher
family income, the immediate treatment was more costly and more effective than control, but
the difference in effectiveness was only marginally higher from that for the low income group.
The cost-effectiveness plane illustrates that differences between the two subgroups were driven
by the cost of productivity loss (Fig 2A). Differences in the cost-effectiveness between the two
income subgroups were even more pronounced when analyses were conducted using DLQI
and WHODAS 2.0 (Table 6, Fig 2B and 2C). For the subgroup with low family income the
immediate treatment was cost-effective (both less costly and more effective compared to the
control) in reducing the number of ADLA episodes and improving health-related quality of
life, but less effective compared to control in reducing disability. For the subgroup with higher
family income the intervention was more effective but more costly than control for all effec-
tiveness outcomes.
Discussion
This is the first study to assess the cost and cost-effectiveness of a lymphoedema management
intervention for people affected by podoconiosis. In the context of a pragmatic randomised
controlled trial, the package of care was effective in reducing the incidence of ADLA episodes
with statistically significant differences at 3 and 12 months after introducing the intervention.
Disease-specific quality of life measured using DLQI was higher in the intervention group at
all data points. We did not find any significant change in disability (WHODAS 2.0) by the end
of the intervention, overall, or by subgroup. The previous, uncontrolled follow-up study [8]
also demonstrated marked (positive) changes in DLQI score (WHODAS was not used in that
study). These changes occurred rapidly, before significant physical changes were observed,
suggesting that quality of life changes are driven by social and emotional factors more than
physical changes. WHODAS 2.0 is less specific about pain, embarrassment and problems with
partners, close relatives and friends than DLQI, and it is possible that this is why we did not
see significant change in WHODAS 2.0 scores.
Table 5. Summary of the cost-effectiveness analyses using different effectiveness outcomes.
Total cost, ETB
mean (SD)
Total effect mean (SD) Difference in cost, ETB
mean (95% CI)
Difference in effect
mean (95% CI)
ICER
ADLA episodes
Control 3,662 (442) 3.39 (0.26) -22
(-86; 43)
0.18
(0.14; 0.22)
Intervention dominates
Immediate treatment 3,640 (424) 3.21 (0.26)
DLQI�
Control 3,662 (442) 11.17 (0.27) -22
(-86; 43)
-2.06
(-2.10; -2.02)
Intervention dominates
Immediate treatment 3,640 (424) 9.11 (0.26)
WHODAS 2.0�
Control 3,662 (442) 22.6 (1.09) -22
(-86; 43)
0.57
(0.40; 0.74)
Intervention less costly and less effective
Immediate treatment 3,640 (424) 23.2 (1.09)
�Lower DLQI and WHODAS 2.0 scores indicate better outcome. DLQI, Dermatology Life Quality Index; WHODAS 2.0, WHO Disability Assessment Schedule 2.0;
ADLA, acute dermatolymphangioadenitis; ETB, Ethiopian Birr; ICER, incremental cost-effectiveness ratio.
https://doi.org/10.1371/journal.pntd.0007780.t005
Cost-effectiveness of podoconiosis lymphoedema treatment in Ethiopia
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007780 October 23, 2019 11 / 19
Cost-effectiveness of podoconiosis lymphoedema treatment in Ethiopia
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007780 October 23, 2019 12 / 19
Our recent process evaluation study (S5 Appendix) explored patients’ perceptions of the
intervention and the impact it had through reducing the frequency of ADLA. Seventy-three
patients who had completed the trial, 10 family members and 8 Community Podoconiosis
Agents took part in Focus Group Discussions or In-Depth Interviews. Overwhelmingly, pro-
cess evaluation participants considered the intervention to be effective in terms of improving
the health, economic and social aspects of patients’ lives, particularly through impact on the
frequency, duration and severity of acute attack episodes. Two representative quotes are given
below. The interviewer’s impression was that even small numerical reductions in ADLA fre-
quency made important differences to patients’ lives. Quotes:
“Previously, I used to have mitchader [acute attack] day-after-day. . .but now, I have it may
be once a month only. . .before, we used to lag behind on tasks such as crop gathering, but now
we finish at the same time as others. . .why, because we’re healthy” (FGD, P010, patient,
male).
“Before she started the treatment, her feet used to get puffed-up, now that’s no mor-
e. . .previously; she used to get ill [acute attack] everyday . . .she recently got ill, but she got bet-
ter immediately and the swelling, has decreased very much. . . wearing shoes helped reduce the
swelling” (IDI, P061, family member, male)” (S5 Appendix).
Fig 1. Cost-effectiveness planes generated using different effectiveness outcomes: the number of ADLA episodes
averted (A), DLQI scores (B) and WHODAS 2.0 scores (C) analysed using GLM. The graph shows 5,000 bootstrap
estimates. ETB, Ethiopian Birr.
https://doi.org/10.1371/journal.pntd.0007780.g001
Table 6. Summary of the cost-effectiveness sub-group analyses based on monthly family income:<1.000 ETB and�1,000 ETB.
Total cost, ETB
mean (SD)
Total effect mean (SD) Difference in cost, ETB
mean (95% CI)
Difference in effect
mean (95% CI)
ICER
ADLA episodes, income <1,000 ETB
Control 3,594 (467) 3.41 (0.27) -111
(-187; -35)
0.18
(0.13; 0.22)
Intervention dominates
Immediate treatment 3,483 (449) 3.23 (0.26)
ADLA episodes, income�1,000 ETB
Control 4,032 (615) 3.32 (0.25) 487
(241; 733)
0.21
(0.11; 0.31)
Intervention more effective and more costly
Immediate treatment 4,518 (612) 3.11 (0.25)
DLQI�, income <1,000 ETB
Control 3,594 (467) 11.00 (0.32) -111
(-187; -35)
-1.9
(-1.95; -1.85)
Intervention dominates
Immediate treatment 3,483 (449) 9.09 (0.31)
DLQI�, income�1,000 ETB
Control 4,032 (615) 12.14 (0.63) 487
(241; 733)
-3.19
(-3.47; -2.92)
Intervention more effective and more costly
Immediate treatment 4,518 (612) 8.95 (0.73)
WHODAS 2.0�, income <1,000 ETB
Control 3,594 (467) 22.2 (1.44) -111
(-187; -35)
0.90
(0.67; 1.14)
Intervention less effective and less costly
Immediate treatment 3,483 (449) 23.11 (1.38)
WHODAS 2.0� , income�1,000 ETB
Control 4,032 (615) 24.71 (1.06) 487
(241; 733)
-0.93
(-1.38; -0.49)
Intervention more effective and more costly
Immediate treatment 4,518 (612) 23.77 (1.11)
�Lower DLQI and WHODAS 2.0 scores indicate better outcome. DLQI, Dermatology Life Quality Index; WHODAS 2.0, WHO Disability Assessment Schedule 2.0;
ADLA, acute dermatolymphangioadenitis; ETB, Ethiopian Birr; ICER, incremental cost-effectiveness ratio.
https://doi.org/10.1371/journal.pntd.0007780.t006
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The cost of community-based lymphoedema management was mainly driven by costs asso-
ciated with delivery of the intervention (transportation, staff salaries, community activities and
training). The cost of hygiene and treatment supplies comprised 22% of the total cost of the
intervention. Given that lymphoedema management intervention was a part of a randomised
controlled trial, there were up-front costs associated with setting up the delivery of care. We
expect the cost of the intervention to go down if it is absorbed into standard government
provision.
Results of cost-effectiveness analyses demonstrate that in three-quarters of estimations the
community-based intervention was more effective and less costly than not intervening, due to
decrease in frequency of ADLA episodes, improved health-related quality of life and reduced
work productivity losses. Our analyses suggest that some subgroups of patients would benefit
more from the intervention, including people who had not attended the school and those liv-
ing on lower incomes.
The only other study to estimate costs and benefits of lymphoedema management exam-
ined a large community-based programme (‘CASA’) in Odisha, India [29]. A non-government
organisation used community health workers to train patients with LF lymphoedema in leg
washing and use of topical antibiotic and antifungal treatments. While the intervention was
similar to that trialled in GoLBeT, it was not identical, for example, bandaging was not used in
India, and socks and shoes were not provided. The programme evaluation, based on an eco-
nomic model, showed per-person savings to be more than 130 times the per-person costs of
the programme. There are several explanations for the much greater cost-benefits of this LF
lymphoedema programme, including the programme being long-established (>10 years) and
the impact on ADLA was extrapolated from observational studies [30]. The model also
included cost of medical care and out-of-pocket expenses for people with LF [29]. A life-time
horizon was assumed in the model, and assumptions were made concerning LF morbidity, life
expectancy and the labour market. The cost of the programme per patient was I$10.00- I
$12.50 over 24 months. It is unclear how these costs were calculated and which costing catego-
ries were included [31].
Unlike the CASA economic study, the results of our analyses were based on individual-level
data, allowing for possible correlations between costs and health outcomes for each partici-
pant. Out-of-pocket medical costs were not considered. Cost of intervention per patient
was calculated over one year and included programme set-up costs. Uncertainty in costs and
outcomes was assessed using non-parametric methods reflecting real-life probability
distributions.
An earlier, uncontrolled study among podoconiosis patients demonstrated highly signifi-
cant improvement in quality of life with treatment [8], as did a preliminary study among
patients with LF lymphoedema in Guyana [32]. In each case, quality of life changes outstripped
clinical changes, suggesting that other, possibly social factors were as important as clinical
effects in improving reported quality of life.
We observed no significant difference between intervention and control groups in reduc-
tion in disability within the 12-month follow-up of GoLBeT. Uncontrolled follow-up of LF
patients on the CASA treatment programme over 24 months demonstrated significant reduc-
tions in disability, also measured using WHODAS 2.0 [33]. The differences may be explained
by the different study designs. In the CASA programme, the greatest improvements in total
Fig 2. Cost-effectiveness planes for patients with monthly family income<1,000 ETB (grey circles) and monthly
family income�1,000 ETB (black circles). The graphs show 5,000 bootstrap estimates for the number of ADLA
episodes (A), DLQI (B) and WHODAS 2.0 (C). ETB, Ethiopian Birr.
https://doi.org/10.1371/journal.pntd.0007780.g002
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disability score were seen at 6 months, with slight rebound at 12 and 24 months, so duration of
follow-up does not seem to explain the difference between studies.
Limitations
The analyses of social and economic outcomes presented in this study have a number of
limitations:
1. Economic evaluation was not planned as a part of this study, therefore costs to other
individuals (e.g. care givers) and health care system (government clinics) were not included
in the economic analyses. There was no government provision of podoconiosis lymphoe-
dema care at the time. However, our results show the community-based lymphoedema
management to be cost effective even when work productivity costs alone are taken into
account.
2. It was not always possible to separate costs associated with intervention and research (e.g.
transportation and workshops). Therefore, the cost of intervention reported in this study
may be inflated.
3. The follow-up period was quite short (12 months), therefore we were unable to capture
long-term effects of the intervention on work productivity and disability. Longer term fol-
low-up seems necessary to capture changes in reported disability and is advised for future
studies.
Conclusions
The results of our economic evaluation suggest that the community-based lymphoedema
intervention can be cost-effective in reducing the frequency of ADLA episodes, improving
health-related quality of life and decreasing work productivity losses. In three-quarters of esti-
mations, the intervention appeared to be cost-saving due to improved work productivity. Sub-
groups of patients who had not attended the school and those living on low income seem to
benefit the most from this intervention.
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